Eckert & Ziegler Strahlen- und Medizintechnik AG

Environmental & Social Information • Oct 13, 2010

News Details

Media | 13 October 2010 13:50

Eckert & Ziegler awards grants to young researchers in nuclear medicine

Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Enterprise

13.10.2010 13:50

Berlin, October 13, 2010. This year's travel grants from Eckert & Ziegler
Strahlen- und Medizintechnik AG (ISIN DE0005659700) have been awarded to
five nuclear medicine scientists from Australia, Germany, the Netherlands
and the United States. The prize-winners were selected by a jury from the
European Association of Nuclear Medicine (EANM) from a total of 534
entries. Work in the fields of oncologic and neurological diagnostic
received recognition. The travel grants, which amount to 1,000 EUR each,
were presented today at the annual congress of the EANM in Vienna to:

M. Mustafa, Germany: The impact of SPECT/CT hybrid imaging in detecting
regional lymph node involvement in T1 papillary thyroid carcinoma:
presenting an update on a bicentric study including 202 patients

N. Zarzhevsky, United States: White Matter Lesions augment Cognitive
Impairments of Dopaminergic Denervation of the Caudate Nucleus in Parkinson
disease

T. Aukema, Netherlands: 18F-FDG PET/CT and diagnostic CT for the prediction
of histopathologic treatment response after epidermal growth factor
receptor tyrosinekinase inhibitor treatment in patients with resectable
NSCLC

J. Beauregard, Australia: The tumoural 'Sink Effect' on the biodistribution
of 68Ga-octreotate: implications for peptide receptor radionuclide therapy

L. Vivash, Australia: The Development of [18F]-Flumazenil-PET for
Localisation of the Epileptogenic Zone in Patients with Medically
Refractory Focal Epilepsy

'The Positron Emission Tomography (PET) imaging technique is the fastest
growing segment on the medical device market. In presenting the 'EANM
Eckert & Ziegler Abstract Award' we wish to encourage young researchers to
present their ideas to a wider audience and to collaborate more in
exchanging ideas with other researchers engaged in the field of nuclear
medicine. We hope that this will help to ensure that the enormous progress
which has been made in medical imaging can soon be transformed into more
precise, faster or cheaper methods of diagnosis and therapy,' explained Dr.
Andreas Eckert, CEO of Eckert & Ziegler.

Eckert & Ziegler AG is one of the world's largest providers of isotope
component technology for radiation therapy and nuclear medicine. The Berlin
based company has 540 employees and is listed at the Frankfurt Stock
exchange.

You can find further information about the Eckert & Ziegler travel grant at
www.ezag.de/en/award_e.html.

Eckert & Ziegler AG, Karolin Riehle, Investor Relations & PR,
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 941084-138, Fax-112, E-mail: karolin.riehle@ezag.de,
www.ezag.com

13.10.2010 Dissemination of a Press Release, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Internet: www.ezag.de

End of Announcement DGAP-Media

---